Isunakinra for Solid Tumors

Baylor Charles A. Simmons Cancer Center, Dallas, TX
Solid TumorsIsunakinra - Biological
All Sexes

Study Summary

This trial will test the safety and tolerability of a new cancer drug, and then study how well it works when combined with another cancer drug.

Eligible Conditions
  • Solid Tumors, Adult

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Two years

Day 49
Proportion of patients who experience DLTs
Proportion of patients who experience decrease of IL-6 or hsCRP by >20%
Two years
Overall survival
Percent of individuals who experience radiographic response
Progression-free survival (PFS)

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor
1 of 1

Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Isunakinra · No Placebo Group · Phase 1 & 2

Isunakinra monotherapy and in combination w PD-(L)1 InhibitorExperimental Group · 2 Interventions: PD-(L)1 Inhibitor, Isunakinra · Intervention Types: Biological, Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: two years

Who is running the clinical trial?

Buzzard PharmaceuticalsLead Sponsor
Baylor Research InstituteOTHER
191 Previous Clinical Trials
186,207 Total Patients Enrolled
Maarten de Chateau, MD, PhDStudy DirectorBuzzard Pharmaceuticals
1 Previous Clinical Trials
27 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are there vacancies available in this clinical trial?

"According to the data available on, this experiment is currently enrolling participants and was initially posted in September 2020 with its most recent update occurring on July 2021." - Anonymous Online Contributor

Unverified Answer

Can you provide a compendium of investigations surrounding Isunakinra?

"Presently, one clinical trial for Isunakinra is actively in progress and none are currently at Phase 3. This research project has a presence in Dallas, Texas with an additional site operating studies." - Anonymous Online Contributor

Unverified Answer

What is the current capacity of this research study?

"Affirmative. According to, this medical trial that was first unveiled on September 1st 2020 is currently recruiting patients. 25 volunteers are required from a single site." - Anonymous Online Contributor

Unverified Answer

Is this venture unprecedented in its methodology?

"At present, Isunakinra is being tested in a single location as part of an ongoing clinical study. This experiment was initiated by Buzzard Pharmaceuticals in 2020 and included 25 participants who successfully completed the Phase 1 & 2 assessment process. 5 additional trials have been conducted since then." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.